Table 1.
Adherence rates with continuous prophylaxis for patients with hemophilia over time
| Data source | Type of study | Time frame | Rate of prophylaxis by disease severity (%)
|
|||
|---|---|---|---|---|---|---|
| Severe | Moderate | Mild | Unknown | |||
| CDC UDC program25 | Observational prospective | 1998–2004 | A: 35.3 | A: 13.4 | A: 0.6 | NA |
| B: 27.1 | B: 6 | B: 0.7 | ||||
| A + B: 34 | A + B: 11 | A + B: 0.7 | ||||
| CDC UDC program26 | Observational prospective | 2005–2009 | A + B: 48 | A + B: 16.2 | A + B: 2.1 | A + B: 27.8 |
| Blanchette et al27 | Survey of North American HTC clinicians* | 2002 | A: 47 | A: 13 | A: 0 | NA |
| B: 30 | B: 3 | B: 0 | ||||
| A + B: 44.2 | A + B: 12.9 | A = B | ||||
| Zappa et al28 | Survey of North American HTC clinicians | 2010 | A: 58 | NA | NA | NA |
| B: 51 | ||||||
| A + B: 56.8 | ||||||
| ATHN data set29 | Registry | 2010–2015 | A: 67.6 | A: 30.1 | A: 4.4 | A: 7.5 |
| B: 60.7 | B: 14.1 | B: 4.5 | B: 6.2 | |||
Note:
*
Patients aged ≤18 years only.
Abbreviations: CDC, Centers for Disease Control and Prevention; UDC, Universal Data Collection; NA, not applicable; HTC, hemophilia-treatment center; ATHN, American Thrombosis and Hemostasis Network; A, FVIII deficiency; B, FIX deficiency.